Currently, PD-L1 expression stands as the sole validated predictive biomarker for PD-1/PD-L1 inhibitors in NSCLC patients, emphasizing the need for precise patient selection to maximize therapeutic benefits. This evidence concerns the gene CD274 and non-small cell lung carcinoma.